Häftad, Engelska, 2027

Emergent Nanotherapeutics in Diabetic Complications

2326 kr

Kommande

Beskrivning

Emergent Nanotherapeutics in Diabetic Complications explores how cutting-edge nanotechnology is transforming the treatment of diabetes-related disorders beyond glycemic control. This comprehensive volume examines targeted, multifunctional nanoplatforms designed to address the wide range of comorbidities linked to diabetes, including vascular complications, metabolic dysfunctions, and impaired wound healing. Structured in five parts, the book spans from current nanoformulation strategies to emerging innovations such as CRISPR-Cas9 delivery, AI-guided nanoparticles, and 3D/4D printed nanostructures.

Bridging the gap between preclinical research and clinical application, it offers valuable guidance on stimuli-responsive systems, biocompatible materials, and regulatory pathways. This is essential resource for medical professionals, biomedical engineers, and pharmaceutical scientists seeking scalable, next-generation solutions for managing diabetic complications through nanomedicine.

Focuses on nanotherapeutics for diabetes-related complications, not just glucose control
Covers nano-drug delivery systems for improved wound healing and comorbidity management
Highlights next-generation technologies like CRISPR-Cas9, AI-driven nanoparticles, and 3D/4D nanostructures
Includes guidance on translational research, clinical developments, and regulatory considerations

Produktinformation

Utgivningsdatum: 2027-04-01
Mått: 191 x 235 x undefined mm
Vikt: 450 g
Format: Häftad
Språk: Engelska
Antal sidor: 440
Förlag: Elsevier Science
ISBN: 9780443449420

Utforska kategorier

Biologi

Mer om författaren

Dr. Awanish Kumar is an Associate Professor of the Department of Biotechnology at the National Institute of Technology, Raipur, Chhattisgarh, India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery. Gunjan Adwani is a Ph.D. researcher in the Department of Biotechnology at the National Institute of Technology, Raipur, India. Her research focuses on nanomedicine, advanced drug delivery systems, and diabetes therapeutics, with a primary focus on optimizing insulin delivery strategies. She holds a Bachelor of Science and a Master of Science in Biotechnology from Pt. Ravishankar Shukla University, Raipur. Her current work involves the development of innovative nanocarrier platforms for targeted antidiabetic drug delivery and the formulation of therapeutic interventions to mitigate diabetic comorbidities.

Betyg & recensioner

0 recensioner

Inga recensioner tillgängliga.